Dexcom Reveals Flex CGM for Type 2 Diabetes Patients

Dexcom has announced Dexcom Flex, a new continuous glucose monitoring (CGM) system designed for adults with type 2 diabetes who aren’t using intensive insulin therapy.

The new system will become available in Germany soon. It’s made for people using basal insulin, oral medications, or GLP-1 receptor agonists, broadening access to CGM tech to a wider type 2 diabetes population.

Dexcom Flex provides 24/7 glucose readings on a smartphone, smartwatch, or receiver, with routine fingerpricks. It features real-time glucose monitoring with optional food an activity logging, optional and customizable low glucose alerts, and personalized glucose insights.

“The development of Dexcom Flex reflects a shift toward personalized diabetes guidance” said Ian Hanson, senior vice president of engineering at Dexcom. “We strongly believe that personalized diabetes care is what helps people adopt the new habits and behavioral changes that lead to meaningful results. Dexcom Flex has been designed to support people earlier in their Type 2 diabetes journey, delivering a more tailored experience while maintaining the accuracy and reliability associated with Dexcom technology.”

Many patients not using intensive insulin therapy have historically had limited access to CGM technology. Germany is among the European countries expanding the use of digital health tools in type 2 diabetes care.

Dexcom cited studies that show CGM use in people with type 2 diabetes can support reduction in diabetes-related hospitalizations. Research has also shown Dexcom CGM systems can help people with type 2 diabetes using basal insulin reduce their HbA1c and increase the time spent in their target glucose range.

“Launching Dexcom Flex in Germany reflects our continued focus on expanding access to CGM,” said Alexander Fröhlich, VP and GM DACH at Dexcom. “As personalization becomes increasingly important in Type 2 diabetes care, Flex enables a more tailored approach to glucose monitoring. By supporting people earlier in their Type 2 journey, before they require intensive insulin therapy, Flex may help improve long‑term health outcomes and contribute to meaningful reductions in diabetes-related complications.”